Comments
New Delhi The Drugs Controller General of India (DCGI) has recommended emergency use authorisation (EUA) for Bharat Biotech’s Covaxin for children between 6 and 12 years.
The DCGI has also recommended EUA for Corbevax (made by Biological E) for children aged 5 to 12 years and Zydus Cadila’s ZyCoV-D for those above 12 years.
Confirming the development, Union Health Minister, Mansukh Mandaviya in a tweet (in Hindi) said: “The approvals will help strengthen India’s fight against Covid-19.”
The subject expert committee (SEC) had suggested amendments to protocols for Covaxin. Among the India-made vaccines, Coaxin is the second-most predominant one after Covishield.
‘Covaxin’ is already administered to children in the age group of 15-18 years apart from adults. The vaccine is administered in two doses, with a gap of 28 days between the first and second doses.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.